Suppr超能文献

2 型糖尿病的疾病负担:使用马斯特里赫特研究估计的疾病成本和生活质量。

Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study.

机构信息

Department of Health Services Research, Maastricht University, Maastricht, The Netherlands.

CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.

出版信息

Diabet Med. 2020 Oct;37(10):1759-1765. doi: 10.1111/dme.14285. Epub 2020 Mar 18.

Abstract

AIMS

To estimate the societal costs and quality of life of people with type 2 diabetes and to compare these results with those of people with normal glucose tolerance or prediabetes.

METHODS

Data from 2915 individuals from the population-based Maastricht Study were included. Costs were assessed through a resource-use questionnaire completed by the participants; cost prices were based on Dutch costing guidelines. Quality of life was expressed in utilities using the Dutch EuroQol 5D-3L questionnaire and the SF-36 health survey. Based on normal fasting glucose and 2-h plasma glucose values, participants were classified into three groups: normal glucose tolerance (n = 1701); prediabetes (n = 446); or type 2 diabetes (n = 768).

RESULTS

Participants with type 2 diabetes had on average 2.2 times higher societal costs than those with normal glucose tolerance (€3,006 and €1,377 per 6 months, respectively) and had lower utilities (0.77 and 0.81, respectively). No significant differences were found between participants with normal glucose tolerance and those with prediabetes. Subgroup analyses showed that higher age, being female and having two or more diabetes-related complications resulted in higher costs (P < 0.05) and lower utilities.

CONCLUSIONS

This study showed that people with type 2 diabetes have substantially higher societal costs and lower quality of life than people with normal glucose tolerance. The results provide important input for future model-based economic evaluations and for policy decision-making.

摘要

目的

评估 2 型糖尿病患者的社会成本和生活质量,并将这些结果与血糖正常或糖尿病前期患者的结果进行比较。

方法

本研究纳入了基于人群的马斯特里赫特研究中的 2915 名个体。通过参与者完成的资源使用问卷评估成本;成本价格基于荷兰成本指南。使用荷兰 EuroQol 5D-3L 问卷和 SF-36 健康调查,以效用表示生活质量。根据正常空腹血糖和 2 小时血浆葡萄糖值,参与者被分为三组:血糖正常(n=1701);糖尿病前期(n=446);或 2 型糖尿病(n=768)。

结果

与血糖正常者相比,2 型糖尿病患者的社会成本平均高出 2.2 倍(分别为 6 个月 3006 欧元和 1377 欧元),效用更低(分别为 0.77 和 0.81)。血糖正常者和糖尿病前期患者之间无显著差异。亚组分析显示,年龄较大、女性以及有两种或更多糖尿病相关并发症会导致更高的成本(P<0.05)和更低的效用。

结论

本研究表明,2 型糖尿病患者的社会成本和生活质量明显低于血糖正常者。研究结果为未来基于模型的经济评估和政策决策提供了重要依据。

相似文献

1
Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study.
Diabet Med. 2020 Oct;37(10):1759-1765. doi: 10.1111/dme.14285. Epub 2020 Mar 18.
5
White Matter Connectivity Abnormalities in Prediabetes and Type 2 Diabetes: The Maastricht Study.
Diabetes Care. 2020 Jan;43(1):201-208. doi: 10.2337/dc19-0762. Epub 2019 Oct 10.
6
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
7
Quality of life and societal costs in patients with dilated cardiomyopathy.
Eur Heart J Qual Care Clin Outcomes. 2024 Jun 20;10(4):334-344. doi: 10.1093/ehjqcco/qcad056.
8
A Systematic Review of the Economic Burden of Type 2 Diabetes in Malaysia.
Int J Environ Res Public Health. 2020 Aug 7;17(16):5723. doi: 10.3390/ijerph17165723.
10
The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke.
BMJ Open. 2015 Nov 27;5(11):e008220. doi: 10.1136/bmjopen-2015-008220.

引用本文的文献

1
Symptoms affecting the development of diabetes: analysis of risk factors with data mining.
BMC Med Inform Decis Mak. 2025 Aug 27;25(1):319. doi: 10.1186/s12911-025-03159-5.
2
Cost of diabetes mellitus and associated factors - an institutional cross-sectional study in Ghana.
BMC Health Serv Res. 2025 Apr 8;25(1):514. doi: 10.1186/s12913-025-12667-z.
3
Effect of administration routes on the efficacy of human umbilical cord mesenchymal stem cells in type 2 diabetic rats.
Front Endocrinol (Lausanne). 2025 Mar 21;16:1536655. doi: 10.3389/fendo.2025.1536655. eCollection 2025.
4
The Burden of Fecal Incontinence: Evaluating the Societal Impact in Terms of Economic Burden and Health-Related Quality of Life.
Neurogastroenterol Motil. 2025 Sep;37(9):e70036. doi: 10.1111/nmo.70036. Epub 2025 Apr 2.
7
Economic burden of Type 2 diabetes in Iran in 2022.
BMC Public Health. 2025 Jan 4;25(1):35. doi: 10.1186/s12889-024-21247-5.
9
Early elevations in arterial pressure: a contributor to rapid depressive symptom emergence in female Zucker rats with metabolic disease?
J Appl Physiol (1985). 2024 Nov 1;137(5):1324-1340. doi: 10.1152/japplphysiol.00586.2024. Epub 2024 Oct 3.

本文引用的文献

1
The Cost of Diabetes Care-An Elephant in the Room.
Diabetes Care. 2018 May;41(5):929-932. doi: 10.2337/dci18-0012.
4
Dutch Tariff for the Five-Level Version of EQ-5D.
Value Health. 2016 Jun;19(4):343-52. doi: 10.1016/j.jval.2016.01.003. Epub 2016 Mar 30.
5
Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study.
Am J Kidney Dis. 2017 Feb;69(2):179-191. doi: 10.1053/j.ajkd.2016.04.017. Epub 2016 Jun 10.
7
Cost-of-illness studies: concepts, scopes, and methods.
Clin Mol Hepatol. 2014 Dec;20(4):327-37. doi: 10.3350/cmh.2014.20.4.327. Epub 2014 Dec 24.
8
Cost-of-illness studies of diabetes mellitus: a systematic review.
Diabetes Res Clin Pract. 2014 Aug;105(2):151-63. doi: 10.1016/j.diabres.2014.03.020. Epub 2014 Apr 18.
9
The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities.
Eur J Epidemiol. 2014 Jun;29(6):439-51. doi: 10.1007/s10654-014-9889-0. Epub 2014 Apr 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验